• Head_banner_01

Rhovac Cancer Cancab Peptide Tshuaj Tiv Thaiv RV001 kom muaj los ntawm Canadian cov cuab yeej fwm

Canada Sijhawm 2022-01-24, Rhovac, lub tuam txhab kws tshuaj tua kab mob RV00 (No. 2710061) Rau nws lub chaw haujlwm Canadal txawj ntse Yav dhau los, lub tuam txhab tau txais cov patents ntsig txog RV001 hauv Tebchaws Asmeskas, Europe thiab Nyij Pooj. Cov nyiaj tau patent no yuav muab kev tiv thaiv dav rau RV001 hauv cov lag luam tseem ceeb thiab tsa lub tuam txhab ua lag luam patent.

Zoo li yav dhau los muab daim ntawv thov patent, daim duab no npog cov tshuaj tiv thaiv kab mob RV001 thiab nws cov kev siv tshuaj tiv thaiv Cancer / tiv thaiv kev cuam tshuam rau cov qog nqaij hlav cancer. Ntawm lawv, rhac yog cov qog-txuam tshuaj antigen (TAA) uas yog Outexpressed hauv ntau cov qog cov qog hom. Thaum tau txais kev pom zoo nyob rau hauv 2028-12 thiab yuav tsum tau txuas ntxiv thaum tau txais daim ntawv pov thawj ntawm kev tiv thaiv ntxiv (CSP).

01 onilcamotide

Onilcamotide yog kev txhaj tshuaj tiv thaiv kab mob Cancerogenic muaj kev tiv thaiv kab mob hauv tsev neeg hauv tsev neeg muaj zog. Subcleous thawj coj ntawm onilcamotide stimulates tus tswv muaj zog tiv thaiv kab mob mount ib qho kev tiv thaiv kab mob mount ib qho kev ua kom tsis muaj zog thiab cytotoxic t loc-qhia cov qog qog nqaij hlav, yog lysing cov qog ntshav.

2020-11, RV001 tau txais kev tsim qauv ceev taug kev los ntawm FDA.

Onilcamotide

02 Kuaj Xyuas Kev Txom Nyem

Nyob rau hauv 2018, lub theem I / Iia kev sim ntawm atilcamotide rau kev kho mob ntawm prostate cancer tau pom zoo, thiab tag nrho ntawm 21 tus neeg mob tau cuv npe. Cov txiaj ntsig tau pom tias onilcamotide muaj kev nyab xeeb thiab zoo zam. Tsis tas li ntawd, cov neeg mob tau tsim muaj zog thiab cov lus teb tsis muaj zog hauv qab no. Xyoo 2021, muaj kev taug xyuas ntawm 19 ntawm cov kev kawm no, qhia tau tias kev kho kom tiav thiab tau txais kev kho mob ntxiv rau antigen (PSA). Cov. Ntawm cov no, 16 kawm tsis muaj kev tshawb nrhiav PSA, thiab 3 yam tau qeeb PSA zuj zus. PSA yog protein protuced los ntawm prostate caj pas thiab yog siv los taug qab cov kev vam meej ntawm kev paub mob qog nqaij hlav cancer.

Hauv 2019, RV001 theem iib cathate, randomized, ob-qhov muag tsis pom kev ntawm kev tsim kho mob prostate los yog kev phais mob / phais / hluav taws xob. Qhov kev xeem ntawv iib yog kev tshawb nrhiav thoob ntiaj teb, kev nrhiav neeg European (Chaw nres nkoj European, Belland, lub teb chaws Yelemees, thiab koom ua tebchaws Yelemees, thiab koom ua tebchaws Yelemees. Qhov kev sib tw ua tiav cov neeg ua haujlwm neeg mob txog 2021-09, nrog tag nrho cov kwv yees li ntawm 175 tus kawm cuv npe, thiab yuav xaus rau 2022h1. Tsis tas li ntawd, Rhovac npaj yuav coj cov ntaub ntawv tshawb nrhiav preforators preclinical tau npaj tseg rau kev nthuav dav ntawm RV001 hauv kev qhia.

Ib qho ntxiv, Pawg Neeg Saib Xyuas Kev Nyab Xeeb kuj tau ua ib qho kev nyab xeeb hauv RV001 hauv 2021-07, thiab tsis muaj kev cuam tshuam nrog Theem Yav Dhau Los Kuv / II Cov txiaj ntsig tau tshwm sim.


Lub Sijhawm Post: Feb-17-2022